Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

I have a PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL), Portugal. I did my post-doctoral research in Malaria with Prof. Maria Mota at Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência for 6 years. Between 2009 and 2014, I have been a Staff Scientist (Programa Ciência 2008) in the T cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, where I continued studying malaria pathogenesis.

February 23, 2015February 23, 2015

Researchers Gain New Insight Into Activation, Exhaustion of Anti-Tumoral T Cells

News

A new study entitled “The Transcription Factor NFAT Promotes Exhaustion of Activated CD8+ T Cells” was published in Immunity, where researchers show that the transcription factor NFAT in the absence of ... Read more

February 11, 2015February 11, 2015

New Population of Regulatory T-cells Could Result in Novel Cancer Immune Therapies

News

Researchers have discovered a novel subpopulation of regulatory T cells that could be used as an early diagnostic biomarker of susceptibility to allergic diseases and could play an important role ... Read more

January 8, 2015

Sacituzumab Govitecan Attributed Fast Track Designation For Triple Negative Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) attributed the Fast Track development program designation to Immunomedics’ sacituzumab govitecan, the company’s main antibody-drug conjugate (ADC). Sacituzumab govitecan is a potential treatment for ... Read more

December 16, 2014December 16, 2014

Research Shows Immunotherapy Drugs Can Improve Outcomes in Hodgkin Lymphoma Patients

News

Promising results on the treatment of Classical Hodgkin lymphoma (cHL) were presented during the 56th Annual Meeting of the American Society of Hematology (ASH) by Dr. Craig H. Moskowitz, Clinical Director of ... Read more

October 29, 2014October 29, 2014

PhosImmune and PureMHC LLC To Co-Discover And Co-Develop Novel Antibodies Against Phosphopeptide Tumor Antigens

News

A new set of antibody-based immunotherapies that mimic T cell receptors (TCRms) to target cancers will be developed by PhosImmune Inc. and Pure MHC LLC, which have recently established a license ... Read more

September 24, 2014September 24, 2014

Merck KGaA Maneuvering For Continued Immuno-Oncology Drug Development

News

Merck KGaA, the Darmstadt-based subsidiary of Merck, is intensively negotiating with possible partners for their investigational cancer immunotherapy drug, anti-PD-L1 agent, and expect to close the partnership at the end of 2014. The ... Read more

September 17, 2014September 17, 2014

New Trial Tests Immunotherapy Vaccine for Lung Cancer

News

Asterias’ new immunotherapy treatment AST-VAC2 will enter into clinical trials in patients with non-small cell lung cancer (NSCLC). The new research initiative is the result of an agreement established between Cancer Research ... Read more